FDA Grants Breakthrough Designation to HeartBeam's At-Home Heart Attack Assessment
BEAT sits 17% above its 52-week low of $0.355.
Summary
HeartBeam received FDA Breakthrough Device Designation for its 3D ECG system to assess potential heart attacks at home. The designation was granted within 30 days, well ahead of the 60-day statutory review period, and provides prioritized FDA review and potential expedited Medicare coverage via the proposed RAPID pathway. This follows the company's completed ALIGN-ACS enrollment and upcoming TCT 2026 data presentation, and comes amid a going concern warning and active $25M ATM offering. The designation validates the technology's potential and accelerates the regulatory path for a pivotal study, with FDA alignment expected in coming months. For a company with a $24.5M market cap and limited cash, this milestone materially improves the risk profile of its lead program.
At the time of this announcement, BEAT was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.5M. The 52-week trading range was $0.36 to $4.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.